Verinata Health

Verinata Health, now a part of Illumina, operates in the prenatal diagnostics market with a focus on maternal and fetal health. The company developed the verifi® non-invasive prenatal test (NIPT), a blood test that analyzes cell-free DNA from a pregnant person's blood to screen for fetal chromosomal abnormalities like Down syndrome, Edwards syndrome, and Patau syndrome.

This technology provides an alternative to more invasive procedures, such as amniocentesis, by offering an early risk assessment. The company's business model centers on the development and commercialization of these diagnostic tests, which are offered to healthcare providers and expectant parents through clinical laboratories. Following its acquisition by Illumina in 2013, Verinata's technology has been integrated into Illumina's broader portfolio of genetic sequencing solutions, expanding its reach within the global genomics market.

Keywords: non-invasive prenatal testing, NIPT, fetal chromosomal abnormalities, maternal-fetal health, genetic screening, cell-free DNA, prenatal diagnostics, molecular diagnostics, trisomy 21, genomics